Omeros price to sales ratio OMER

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 2.0×; May 2022
10-year median: 12.7×
10-year range: 2.0× to 33.0×
Peer median: 1.7×

Omeros' price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in May 2022, at 2.0×.

On the days it had one over the last ten years, its median was 12.7×, from 2.0× in May 2022 to 33.0× in Feb 2019.

Price to sales ratio over time

median 12.7×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2022	2.0×	2.0×	5.0×
2021	4.4×	4.4×	16.7×
2020	9.1×	5.4×	9.6×
2019	7.4×	6.5×	33.0×
2018	26.3×	7.5×	32.5×
2017	14.6×	11.0×	24.3×
2016	12.0×	10.5×	88.6×
2015	85.2×	72.9×	148×
2014	131×	113×	139×
2013	111×	16.8×	111×
2012	24.7×	24.7×	62.2×

Against its peers

Companies in Drug Manufacturers - General nearest Omeros' size, closest first, today.

Company	Price to sales ratio
OMEROmeros	n/m
AMPHAmphastar Pharmaceuticals	1.5×
PCRXPacira BioSciences	1.9×
ANABAnaptysbio	n/m
PAHCPhibro Animal Health	1.0×
ANIPANI Pharmaceuticals	1.7×
ABUSArbutus Biopharma	4.6×
COLLCollegium Pharmaceutical	0.9×
HRMYHarmony Biosciences	2.2×
PBHPrestige Consumer Healthcare	2.0×
CRMDCorMedix	1.3×
Peer median	1.7×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Omeros

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.